Tvgn stock price momentum faded in late trading

Momentum faded in late trading, with tvgn stock price slipping to $14. Regulus Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. “With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,” said Ryan Saadi , founder and CEO of Tevogen Bio. tvgn stock price ended the day at $14.85, with analysts highlighting strong forward guidance. The media and entertainment sector is poised for strategic mergers, potentially boosting valuations in the next fiscal quarter.